Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2012

01-07-2012 | Endocrine Tumors

Sestamibi-Negative Patients: To Operate or Image?

Authors: Carrie C. Lubitz, MD, MPH, Herbert Chen, MD

Published in: Annals of Surgical Oncology | Issue 7/2012

Login to get access

Excerpt

Parathyroidectomy is accepted as the most durable and cost-effective treatment for patients with primary hyperparathyroidism, with reported cure rates over 97 %.1,2 Surgical cure prevents—and in some cases reverses—complications such as frequency of nephrolithiasis, osteoporosis, cardiovascular disease, and neurocognitive symptoms.3‐7 The large prevalence of single-gland disease has led to the practice shift to focused parathyroidectomy, requiring preoperative localization.8 Moreover, most patients in the United States present with mild or asymptomatic disease with minor biochemical abnormalities, making management increasingly challenging. …
Literature
1.
Siperstein A, Berber E, Barbosa GF, et al. Predicting the success of limited exploration for primary hyperparathyroidism using ultrasound, sestamibi, and intraoperative parathyroid hormone: analysis of 1158 cases. Ann Surg. 2008;248:420–8.PubMed
2.
Udelsman R, Lin Z, Donovan P. The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Ann Surg. 2011;253:585–91.PubMedCrossRef
3.
The American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons position statement on the diagnosis and management of primary hyperparathyroidism. Endocr Pract. 2005;11:49–54.
4.
Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249–55.PubMedCrossRef
5.
Udelsman R, Pasieka JL, Sturgeon C, Young JE, Clark OH. Surgery for asymptomatic primary hyperparathyroidism: proceedings of the Third International Workshop. J Clin Endocrinol Metab. 2009;94:366–72.PubMedCrossRef
6.
Zanocco K, Angelos P, Sturgeon C. Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism. Surgery. 2006;140:874–81.PubMedCrossRef
7.
Pinchot SN, Chen H. Non-operative management of primary hyperparathyroidism: the exception rather than the rule. Exp Rev Endocrinol Metab. 2009;4:553–63.CrossRef
8.
Greene AB, Butler RS, McIntyre S, et al. National trends in parathyroid surgery from 1998 to 2008: a decade of change. J Am Coll Surg. 2009;209:332–43.PubMedCrossRef
9.
Bilezikian JP, Khan AA, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop. J Clin Endocrinol Metab. 2009;94:335–9.PubMedCrossRef
10.
Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. Ann Surg Oncol. 2012;19:577–83.PubMedCrossRef
11.
Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. Would scan, but which scan? A cost-utility analysis to optimize preoperative imaging for primary hyperparathyroidism. Surgery. 2011;150:1286–94.PubMedCrossRef
12.
Rodgers SE, Hunter GJ, Hamberg LM, et al. Improved preoperative planning for directed parathyroidectomy with 4-dimensional computed tomography. Surgery. 2006;140:932–40.PubMedCrossRef
13.
Chen H, Sippel RS, Schaefer S. The effectiveness of radioguided parathyroidectomy in patients with negative technetium tc 99 m-sestamibi scans. Arch Surg. 2009;144:643–8.PubMedCrossRef
Metadata
Title
Sestamibi-Negative Patients: To Operate or Image?
Authors
Carrie C. Lubitz, MD, MPH
Herbert Chen, MD
Publication date
01-07-2012
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-012-2369-4

Other articles of this Issue 7/2012

Annals of Surgical Oncology 7/2012 Go to the issue

Gynecologic Oncology

Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer

Pancreatic Tumors

Clinical Significance of Folate Receptor β–expressing Tumor-associated Macrophages in Pancreatic Cancer

Gastrointestinal Oncology

The Treatment of Peritoneal Carcinomatosis of Colorectal Cancer with Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Peroperative Chemotherapy (HIPEC) with Oxaliplatin: A Belgian Multicentre Prospective Phase II Clinical Study

Colorectal Cancer

Diagnostic Accuracy of MRI for Assessment of T Category, Lymph Node Metastases, and Circumferential Resection Margin Involvement in Patients with Rectal Cancer: A Systematic Review and Meta-analysis

Colorectal Cancer

The Relationship of Lymph Node Evaluation and Colorectal Cancer Survival After Curative Resection: A Multi-Institutional Study

Endocrine Tumors

Pancreatic Neuroendocrine Tumors: Radiographic Calcifications Correlate with Grade and Metastasis